TQB6411 / Sino Biopharm - LARVOL DELTA

APPLICATION FOR CLINICAL TRIAL OF “TQB6411 (EGFR/C-MET BISPECIFIC ADC)” ACCEPTED BY CDE (HKEXnews) - "The board of directors (the 'Board') of Sino Biopharmaceutical Limited (the 'Company', togetherwith its subsidiaries, the 'Group') announces that the application for clinical trial of the Group’s selfdeveloped 'TQB6411 (EGFR/c-Met bispecific ADC)' has been submitted to and accepted by the Centerfor Drug Evaluation (CDE) of the National Medical Products Administration of China....TQB6411 is an antibody-drug conjugate (ADC) targeting EGFR and c-Met."

New trial • Oncology